Phathom Pharmaceuticals, Inc. (PHAT) SEC filings

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30

$6.06−0.17 (-2.73%)

Close on Nov 13, 2026Market cap $492.63MP/E –Yield –

SEC filings

40 of Phathom Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Current report	8-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	8-K	Sep 29, 2026	Sep 29, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jul 30, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jun 23, 2026	Jun 23, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 21, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 19, 2026	Apr 7, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Jan 7, 2026	Jan 8, 2026	SEC EDGAR
Current report	8-K	Jan 7, 2026	Jan 7, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2025	Nov 4, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 30, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 25, 2025	Oct 27, 2025	SEC EDGAR
Current report	8-K	Oct 2, 2025	Oct 6, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 16, 2025	Jun 16, 2025	SEC EDGAR
Current report	8-K	Jun 3, 2025	Jun 9, 2025	SEC EDGAR
Current report	8-K	Jun 6, 2025	Jun 6, 2025	SEC EDGAR
Current report	8-K	May 1, 2025	May 1, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 1, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2025	Apr 23, 2025	SEC EDGAR
Current report	8-K	Apr 11, 2025	Apr 16, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Apr 1, 2025	SEC EDGAR
Current report	8-K	Mar 6, 2025	Mar 6, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 6, 2025	SEC EDGAR
Current report	8-K	Dec 11, 2024	Dec 11, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Aug 19, 2024	Aug 19, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 18, 2024	Jul 18, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Phathom Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PHAT.

Compare: PHAT vs SNDX · PHAT vs AKBA · PHAT vs RIGL · PHAT vs ARDX · PHAT vs IRWD

Revenue growth86.8% · median 16.8%

Gross margin80.7% · median 89.6%

Operating margin-9.3% · median -7.9%

Net margin-30.2% · median -12.4%

Company	Revenue	Growth
ARDX	$450.89M	+16.8%
IRWD	$400.30M	+18.1%
SNDX	$289.68M	+159.7%
RIGL	$288.21M	+2.2%
PHAT	$274.88M	+86.8%
AKBA	$197.20M	-12.4%

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 371
Held by institutions: 88.7%
Auditor: Ernst & Young LLP
SEC CIK: 1783183

Advertisement
300 × 250

See a number that looks wrong?